User login
Key clinical point: Intradermal (ID) hepatitis B virus (HBV) vaccination with topical imiquimod pretreatment (ID-Imq) to the injection site was safe and provided superior seroprotection compared with intramuscular (IM) HBV vaccination with aqueous cream pretreatment (IM-Aq) in patients with inflammatory bowel disease (IBD).
Major finding: Patients who received ID-Imq vs. IM-Aq showed a significantly higher seroprotection rate at 12 months (91% vs. 69%; P = .005). Overall, 59% and 55% of patients in the ID-Imq and IM-Aq groups reported any adverse events, respectively, with local reactions being more common in the ID-Imq group.
Study details: Findings are from a phase 2 and 3 trial including 104 patients with IBD and no evidence of HBV infection or immunity who were randomly assigned to receive ID-Imq (n = 53) or IM-Aq (n = 51) at 0, 1, and 6 months.
Disclosures: This study was partly funded by a Young Investigator Research Grant from the Hong Kong College of Physicians. WK Leung reported serving as a speaker for Ferring, Janssen, and Takeda.
Source: Ko K-L et al. Clinical trial: Intra-dermal hepatitis B vaccination with topical imiquimod versus intra-muscular hepatitis B vaccination in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2022 (May 11). Doi: 10.1111/apt.16970
Key clinical point: Intradermal (ID) hepatitis B virus (HBV) vaccination with topical imiquimod pretreatment (ID-Imq) to the injection site was safe and provided superior seroprotection compared with intramuscular (IM) HBV vaccination with aqueous cream pretreatment (IM-Aq) in patients with inflammatory bowel disease (IBD).
Major finding: Patients who received ID-Imq vs. IM-Aq showed a significantly higher seroprotection rate at 12 months (91% vs. 69%; P = .005). Overall, 59% and 55% of patients in the ID-Imq and IM-Aq groups reported any adverse events, respectively, with local reactions being more common in the ID-Imq group.
Study details: Findings are from a phase 2 and 3 trial including 104 patients with IBD and no evidence of HBV infection or immunity who were randomly assigned to receive ID-Imq (n = 53) or IM-Aq (n = 51) at 0, 1, and 6 months.
Disclosures: This study was partly funded by a Young Investigator Research Grant from the Hong Kong College of Physicians. WK Leung reported serving as a speaker for Ferring, Janssen, and Takeda.
Source: Ko K-L et al. Clinical trial: Intra-dermal hepatitis B vaccination with topical imiquimod versus intra-muscular hepatitis B vaccination in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2022 (May 11). Doi: 10.1111/apt.16970
Key clinical point: Intradermal (ID) hepatitis B virus (HBV) vaccination with topical imiquimod pretreatment (ID-Imq) to the injection site was safe and provided superior seroprotection compared with intramuscular (IM) HBV vaccination with aqueous cream pretreatment (IM-Aq) in patients with inflammatory bowel disease (IBD).
Major finding: Patients who received ID-Imq vs. IM-Aq showed a significantly higher seroprotection rate at 12 months (91% vs. 69%; P = .005). Overall, 59% and 55% of patients in the ID-Imq and IM-Aq groups reported any adverse events, respectively, with local reactions being more common in the ID-Imq group.
Study details: Findings are from a phase 2 and 3 trial including 104 patients with IBD and no evidence of HBV infection or immunity who were randomly assigned to receive ID-Imq (n = 53) or IM-Aq (n = 51) at 0, 1, and 6 months.
Disclosures: This study was partly funded by a Young Investigator Research Grant from the Hong Kong College of Physicians. WK Leung reported serving as a speaker for Ferring, Janssen, and Takeda.
Source: Ko K-L et al. Clinical trial: Intra-dermal hepatitis B vaccination with topical imiquimod versus intra-muscular hepatitis B vaccination in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2022 (May 11). Doi: 10.1111/apt.16970